Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Artemis II astronauts say they're "ready to go" for moon launch - 2Pick Your Favored kind of soup
- 3AI is making spacecraft propulsion more efficient – and could even lead to nuclear-powered rockets
- 4Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- 5Giant ‘toothed’ birds flew over Antarctica 40 million to 50 million years ago
- Find the Interesting Universe of Computerized reasoning: the Capability of man-made intelligence
- Figure out How to Establish a long term connection with Your Handshake
- Partner of crime boss Steven Lyons arrested in Dubai
- Which camera do you believe is great for first-time clients? !
- She just became the first wheelchair user to travel to space
- Which Kind of Pet Makes the Incomparable Buddy?
- Taylor Momsen explains why she quit 'Gossip Girl': 'I really didn't want to be there'
- Huge solar flare no threat to Artemis 2 astronaut launch to the moon, NASA says
- The Manual for Electric Vehicles that will be hot merchants in 2023
